| Title | Authors (identified) | Published In | Identifier(s) | Topic | Published Date | Match? |
|---|
| Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus | [1]Antonio Viúdez, [2]Guillermo Crespo, [3]María Luisa Gómez Dorronsoro, [4]Imanol Arozarena, [5]Juan Jesús Marín-Méndez, [6]Ana Custodio, [7]Marta Benavent, [8]Saioa Goñi, [9]Beatriz García-Paredes, [10]Jorge Hernando, [11]Maika Durantez, [12]Vicente Alonso, [13]María Del Carmen Riesco, [14]Carlos López, ... [Full author list] | Pancreatology [missing] | DOI: 10.1016/J.PAN.2020.12.009 [ORCID]
PubMed: 33358592 [ORCID]
| immunohistochemistry [missing] | 2020-12-19 | |
| Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR? | [1]Ruth Vera, [2]Elena Mata, [3]Encarna González, [4]Ignacio Juez, [5]Vicente Alonso, [6]Patricia Iranzo, [7]Nieves P Martínez, [8]Carlos López, [9]José M Cabrera, [10]María J Safont, [11]Ana Ruiz-Casado, [12]Mercedes Salgado, [13]Beatriz González, [14]Pilar Escudero, [15]Fernando Rivera, [16]Carles Pericay [Full author list] | International Journal of Colorectal Disease [missing] | DOI: 10.1007/S00384-020-03509-X [ORCID]
PubMed: 32062727 [ORCID]
| aflibercept [missing] | 2020-02-15 | |
| Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study) | [1]Mª Pilar Solis-Hernandez, [2]Ana Fernandez Del Valle, [3]Alberto Carmona-Bayonas, [4]Rocio Garcia-Carbonero, [5]Ana Custodio, [6]Marta Benavent, [7]Teresa Alonso Gordoa, [8]Bárbara Nuñez-Valdovino, [9]Manuel Sanchez Canovas, [10]Ignacio Matos, [11]Vicente Alonso, [12]Carlos Lopez, [13]Antonio Viudez, [14]Marta Izquierdo, [15]David Calvo-Temprano, [16]Enrique Grande, [17]Jaume Capdevila, [18]Paula Jimenez-Fonseca [Full author list] | British Journal of Cancer [missing] | DOI: 10.1038/S41416-019-0558-7 [ORCID]
PubMed: 31477779 [ORCID]
| | 2019-09-03 | |
| Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02) | [1]Xabier García-Albéniz, [2]Vicente Alonso, [3]Pilar Escudero, [4]Miguel Méndez, [5]Javier Gallego, [6]Jose Ramon Rodríguez, [7]Antonia Salud, [8]Julen Fernández-Plana, [9]Hermini Manzano, [10]Montserrat Zanui, [11]Ester Falcó, [12]Jaime Feliu, [13]Mireia Gil, [14]Carlos Fernández-Martos, [15]Uriel Bohn, [16]Carmen Alonso, [17]Verónica Calderero, [18]Federico Rojo, [19]Miriam Cuatrecasas, [20]Joan Maurel [Full author list] | Oncologist [missing] | DOI: 10.1634/THEONCOLOGIST.2018-0728 [ORCID]
PubMed: 31235483 [ORCID]
| colorectal cancer [missing]; biomarker [missing] | 2019-06-24 | |
| Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients | [1]Vicente Alonso, [2]Pilar Escudero, [3]Carlos Fernández-Martos, [4]Antonia Salud, [5]Miguel Méndez, [6]Javier Gallego, [7]Jose-R Rodriguez, [8]Marta Martín-Richard, [9]Julen Fernández-Plana, [10]Hermini Manzano, [11]José-Carlos Méndez, [12]Monserrat Zanui, [13]Esther Falcó, [14]Mireia Gil-Raga, [15]Federico Rojo, [16]Miriam Cuatrecasas, [17]Jaime Feliu, [18]Xabier García-Albéniz, [19]Joan Maurel [Full author list] | Neoplasia [missing] | DOI: 10.1016/J.NEO.2018.05.004 [ORCID]
PubMed: 29842993 [ORCID]
| colorectal cancer [missing]; cetuximab [missing]; metastatic colon cancer [missing] | 2018-05-26 | |
| Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer | [1]Jordi Codony-Servat, [2]Miriam Cuatrecasas, [3]Elena Asensio, [4]Carla Montironi, [5]Anna Martínez-Cardús, [6]Mercedes Marín-Aguilera, [7]Carlos Horndler, [8]Eva Martínez-Balibrea, [9]Michele Rubini, [10]Pedro Jares, ..., [13]Lydia Gaba, [14]Marta Martín-Richard, [15]Vicente Alonso, [16]Pilar Escudero, [17]Carlos Fernández-Martos, ... [Full author list] | British Journal of Cancer [missing] | DOI: 10.1038/BJC.2017.279 [ORCID]
PubMed: 29123263 [ORCID]
| colorectal cancer [missing] | 2017-11-09 | |
| Current controversies in the management of metastatic colorectal cancer | [1]Ruth Vera, [2]Vicente Alonso, [3]Javier Gállego, [4]Encarnación González, [5]Carmen Guillen Ponce, [6]Carles Pericay, [7]Fernando Rivera, [8]M José Safont, [9]Manuel Valladares-Ayerbes [Full author list] | Cancer Chemotherapy and Pharmacology [missing] | DOI: 10.1007/S00280-015-2808-6 [ORCID]
PubMed: 26113053 [ORCID]
| colorectal cancer [missing] | 2015-06-26 | |
| A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features | [1]Ramon Salazar, [2]Jaume Capdevila, [3]Berta Laquente, [4]Jose Luis Manzano, [5]Carles Pericay, [6]Mercedes Martínez Villacampa, [7]Carlos López, [8]Ferran Losa, [9]Maria Jose Safont, [10]Auxiliadora Gómez, [11]Vicente Alonso, [12]Pilar Escudero, [13]Javier Gallego, [14]Javier Sastre, [15]Cristina Grávalos, [16]Sebastiano Biondo, [17]Amalia Palacios, [18]Enrique Aranda [Full author list] | BMC Cancer [missing] | DOI: 10.1186/S12885-015-1053-Z [ORCID]
PubMed: 25886378 [ORCID]
| bevacizumab [missing]; chemoradiotherapy [missing] | 2015-02-26 | |
| Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). | [1]Julen Fernandez-Plana, [2]Carlos Pericay, [3]Guillermo Quintero, [4]Vicente Alonso, [5]Antonieta Salud, [6]Miguel Mendez, [7]Mercedes Salgado, [8]Eugeni Saigi, [9]Luis Cirera, [10]ACROSS Study Group [Full author list] | BMC Cancer [missing] | DOI: 10.1186/1471-2407-14-865 [ORCID]
PubMed: 25417182 [ORCID]
| colorectal cancer [missing]; cetuximab [missing]; phase II clinical trial [missing]; metastatic colon cancer [missing] | 2014-11-22 | |
| Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial | [1]Carlos Fernandez-Martos, [2]Gina Brown, [3]Rafael Estevan, [4]Antonia Salud, [5]Clara Montagut, [6]Joan Maurel, [7]Maria Jose Safont, [8]Jorge Aparicio, [9]Jaime Feliu, [10]Ruth Vera, [11]Vicente Alonso, [12]Javier Gallego, [13]Marta Martin, [14]Miguel Pera, [15]Enrique Sierra, [16]Javier Serra, [17]Salvadora Delgado, [18]Jose V Roig, [19]Jesus Santos, [20]Carles Pericay [Full author list] | Oncologist [missing] | DOI: 10.1634/THEONCOLOGIST.2014-0233 [ORCID]
PubMed: 25209376 [ORCID]
| adenocarcinoma [missing]; chemotherapy [missing]; multicenter clinical trial [missing]; phase II clinical trial [missing] | 2014-09-10 | |
| RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy | [1]Virginia Alonso-Espinaco, [2]Miriam Cuatrecasas, [3]Vicente Alonso, [4]Pilar Escudero, [5]Maribel Marmol, [6]Carlos Horndler, [7]Javier Ortego, [8]Rosa Gallego, [9]Jordi Codony-Servat, [10]Xabier Garcia-Albeniz, [11]Pedro Jares, [12]Antoni Castells, [13]Juan J Lozano, [14]Rafael Rosell, [15]Joan Maurel [Full author list] | European Journal of Cancer [missing] | DOI: 10.1016/J.EJCA.2014.04.019 [ORCID]
PubMed: 24833563 [ORCID]
| colorectal cancer [missing]; chemotherapy [missing]; overexpression [missing]; metastatic colon cancer [missing] | 2014-05-12 | |
| Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study | [1]Marta Martín-Richard, [2]Bartomeu Massutí, [3]Eva Pineda, [4]Vicente Alonso, [5]Maribel Marmol, [6]Daniel Castellano, [7]Emilio Fonseca, [8]Antonio Galán, [9]Marta Llanos, [10]Maria Angeles Sala, [11]Carlos Pericay, [12]Fernando Rivera, [13]Javier Sastre, [14]Angel Segura, [15]Maria Quindós, [16]Pascal Maisonobe, [17]TTD (Tumores del Tracto Digestivo) Study Group [Full author list] | BMC Cancer [missing] | DOI: 10.1186/1471-2407-13-427 [ORCID]
PubMed: 24053191 [ORCID]
| multicenter clinical trial [missing] | 2013-09-20 | |
| Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer | [1]Jordi Codony-Servat, [2]Xabier Garcia-Albeniz, [3]Carles Pericay, [4]Vicente Alonso, [5]Pilar Escudero, [6]Carlos Fernández-Martos, [7]Rosa Gallego, [8]Eva Martínez-Balibrea, [9]Anna Martínez-Cardús, [10]Eva Martinez-Balibrea, [11]Joan Maurel [Full author list] | Medical Oncology [missing] | DOI: 10.1007/S12032-012-0428-0 [ORCID]
PubMed: 23338968 [ORCID]
| colorectal cancer [missing]; irinotecan [missing]; cetuximab [missing] | 2013-01-22 | |
| Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer | [1]Alberto Muñoz, [2]Carles Pericay, [3]Carlos García-Girón, [4]Vicente Alonso, [5]Rosario Dueñas, [6]Luis Cirera, [7]Fernando Rivera, [8]Esther Falcó, [9]Iñaki Alvarez Bustos, [10]Antonia Salud [Full author list] | Oncology Research [missing] | DOI: 10.3727/096504014X13887748696743 [ORCID]
PubMed: 24762224 [ORCID]
| colorectal cancer [missing]; bevacizumab [missing]; capecitabine [missing]; oxaliplatin [missing] | 2013-01-01 | |
| Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy. | [1]María Dolores Giráldez, [2]Juan José Lozano, [3]Míriam Cuatrecasas, [4]Virginia Alonso-Espinaco, [5]Joan Maurel, [6]Maribel Mármol, [7]Carlos Hörndler, [8]Javier Ortego, [9]Vicente Alonso, [10]Pilar Escudero, [11]Gina Ramírez, [12]Christoph Petry, [13]Luis Lasalvia, [14]Kerstin Bohmann, [15]Ralph Wirtz, [16]Aurea Mira, [17]Antoni Castells [Full author list] | International Journal of Cancer [missing] | DOI: 10.1002/IJC.27747 [ORCID]
PubMed: 22833293 [ORCID]
| colon cancer [missing] | 2012-08-12 | |
| Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer. | [1]Ramon Salazar, [2]Matilde Navarro, [3]Ferran Losa, [4]Vicente Alonso, [5]Manel Gallén, [6]Fernando Rivera, [7]Manuel Benavides, [8]Pilar Escudero, [9]Encarnación González, [10]Bartomeu Massutí, [11]Auxiliadora Gómez, [12]Margarita Majem, [13]Enrique Aranda [Full author list] | Clinical and Translational Oncology [missing] | DOI: 10.1007/S12094-012-0846-7 [ORCID]
PubMed: 22855141 [ORCID]
| capecitabine [missing]; oxaliplatin [missing] | 2012-07-11 | |
| Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study. | [1]Carlos Hörndler, [2]Rosa Gallego, [3]Xabier García-Albeniz, [4]Virginia Alonso-Espinaco, [5]Vicente Alonso, [6]Pilar Escudero, [7]Mireya Jimeno, [8]Javier Ortego, [9]Jordi Codony-Servat, [10]Carlos Fernández-Martos, [11]Ana Calatrava, [12]Mercedes Marín-Aguilera, [13]Jenifer Muñoz, [14]Sergi Castellví-Bel, [15]Antoni Castells, [16]Michele Rubini, [17]Pere Gascón, [18]Joan Maurel [Full author list] | Cancer Biology and Therapy [missing] | DOI: 10.4161/CBT.11.2.13839 [ORCID]
PubMed: 21099348 [ORCID]
| phosphorylation [missing]; cetuximab [missing] | 2011-01-15 | |
| Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. | [1]Xabier Garcia-Albeniz, [2]Carles Pericay, [3]Virginia Alonso-Espinaco, [4]Vicente Alonso, [5]Pilar Escudero, [6]Carlos Fernández-Martos, [7]Rosa Gallego, [8]Pere Gascón, [9]Sergi Castellví-Bel, [10]Joan Maurel [Full author list] | Tumor Biology [missing] | DOI: 10.1007/S13277-010-0136-3 [ORCID]
PubMed: 21104178 [ORCID]
| colorectal cancer [missing]; irinotecan [missing]; cetuximab [missing] | 2010-11-23 | |
| Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer | [1]José-María Roca, [2]Vicente Alonso, [3]Carles Pericay, [4]Pilar Escudero, [5]Antonieta Salud, [6]Ferrán Losa, [7]Luis-Jesús López, [8]Imma Guasch, [9]Miguel Méndez, [10]Guillermo Quintero-Aldana, ... [Full author list] | Chemotherapy [missing] | DOI: 10.1159/000313527 [ORCID]
PubMed: 20407241 [ORCID]
| colorectal cancer [missing]; irinotecan [missing]; cetuximab [missing] | 2010-04-21 | |
| Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defi | [1]Carlos Fernández-Martos, [2]Carles Pericay, [3]Jorge Aparicio, [4]Antonieta Salud, [5]Mariajose Safont, [6]Bertomeu Massuti, [7]Ruth Vera, [8]Pilar Escudero, [9]Joan Maurel, [10]Eugenio Marcuello, [11]Jose Luis Mengual, [12]Eugenio Saigi, [13]Rafael Estevan, [14]Moises Mira, [15]Sonia Polo, [16]Ana Hernandez, [17]Manuel Gallen, [18]Fernando Arias, [19]Javier Serra, [20]Vicente Alonso [Full author list] | Journal of Clinical Oncology [missing] | DOI: 10.1200/JCO.2009.25.8541 [ORCID]
PubMed: 20065174 [ORCID]
| capecitabine [missing]; oxaliplatin [missing]; chemoradiotherapy [missing] | 2010-01-11 | |
| Postoperative radiochemotherapy in rectal cancer comparison of two combination schemes: alternating versus concomitant | [1]Javier Valencia, [2]Ricardo Escó, [3]Sofía Polo, [4]Natividad Bascón, [5]Pilar Escudero, [6]Vicente Alonso [Full author list] | Tumori [missing] | DOI: 10.1177/030089160409000210 [ORCID]
PubMed: 15237585 [ORCID]
| chemoradiotherapy [missing] | 2004-03-01 | |